{"id":39662,"date":"2026-09-29T09:45:00","date_gmt":"2026-09-29T13:45:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=39662"},"modified":"2026-09-18T09:02:05","modified_gmt":"2026-09-18T13:02:05","slug":"your-340b-contract-pharmacy-network-is-working-off-a-different-generic-entry-date-than-your-legal-team","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/your-340b-contract-pharmacy-network-is-working-off-a-different-generic-entry-date-than-your-legal-team\/","title":{"rendered":"Your 340B Contract Pharmacy Network Is Working Off a Different Generic Entry Date Than Your Legal Team"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

DrugPatentWatch<\/strong> tracks generic entry dates for a living, and one pattern shows up over and over in support calls from hospital pharmacy and legal affairs teams: two departments at the same covered entity, looking at the same drug, and citing two different dates for when it goes generic. Neither team is wrong. They are answering two different questions.<\/p>\n\n\n\n

The Short Answer<\/h2>\n\n\n\n

A drug’s “generic entry date” is not one fact. It is at least three separate facts that happen to share a name: the date a patent or exclusivity period legally expires, the date a confidential litigation settlement actually permits a generic to launch, and the date a covered entity’s contract pharmacy network, third-party administrator (TPA), and 340B accumulator systems reflect that change in pricing. Legal and regulatory affairs teams generally track the first two. 340B contract pharmacy operations generally react to manufacturer notices and drug-file updates tied to the third. Those calendars do not update on the same schedule, and the gap between them creates two distinct risks: paying more than necessary for a drug that already qualifies for the 340B “penny pricing” floor, or mishandling an NDC transition in a way that raises diversion or duplicate discount exposure.<\/p>\n\n\n\n

The Findings That Matter<\/h2>\n\n\n\n
    \n
  1. A generic entry date written into a patent settlement is legally binding and often confidential.<\/strong> Standard licensing language defines it as “certain or contingent” on events the public cannot observe in real time [19].<\/li>\n\n\n\n
  2. Settled entry dates can move a full year earlier than the public patent-expiration date would suggest.<\/strong> Gilead’s 2014 settlement with Teva set a Truvada generic entry date of September 30, 2020, about a year ahead of the emtricitabine patent’s expected September 2021 expiration [25][26].<\/li>\n\n\n\n
  3. Settled entry dates can also sit more than a decade in the future and only be found in a securities filing.<\/strong> Collegium’s 2020 settlement with Teva over Xtampza ER set a licensed entry date of “on or after September 2, 2033,” disclosed in an SEC Form 8-K, not in the Orange Book [30].<\/li>\n\n\n\n
  4. The 340B ceiling price formula is NDC-specific and rate-sensitive to a drug’s brand-or-generic classification.<\/strong> It equals Average Manufacturer Price (AMP) minus Unit Rebate Amount (URA), with a minimum URA of 23.1% for most brand drugs versus 13% for generic and over-the-counter drugs [9][11].<\/li>\n\n\n\n
  5. A large share of 340B-purchased generics price at the statutory floor, not a calculated discount.<\/strong> HRSA’s “penny pricing” policy sets the ceiling price at $0.01 whenever AMP minus URA would otherwise be zero or negative, a result common for generics with several manufacturers and thin margins [11][14].<\/li>\n\n\n\n
  6. The 340B market has never been larger or more concentrated in specialty drugs<\/strong>, where patent life, exclusivity stacking, and settlement complexity are highest. Covered entities purchased $100.0 billion in covered outpatient drugs in 2025, with specialty products accounting for 61.9% of that spend on just 38.1% of units [1][7].<\/li>\n<\/ol>\n\n\n\n

    Two Definitions of “Generic Entry Date” That Rarely Match<\/h2>\n\n\n\n

    Every 340B covered entity operates two parallel systems that both claim to track when a drug goes generic. They are not built from the same inputs.<\/p>\n\n\n\n

    What Legal and Regulatory Affairs Teams Track<\/h3>\n\n\n\n

    A pharmaceutical company’s legal and regulatory affairs function, and the outside counsel who negotiate Paragraph IV settlements, work from primary legal instruments: the patents themselves, the Orange Book listing, the litigation docket, and, critically, the settlement agreement. Under the Hatch-Waxman framework, a generic applicant filing an Abbreviated New Drug Application (ANDA) with a Paragraph IV certification must notify the brand company, which then has 45 days to sue [20]. A timely suit triggers a 30-month stay on FDA approval unless the case resolves sooner [21].<\/p>\n\n\n\n

    Most Paragraph IV cases never reach a verdict. A National Bureau of Economic Research study of drug patent settlements found that litigation “initiates confidential settlement negotiations between the parties,” and that because more than half of challenged brand patents do not survive court scrutiny, both sides often prefer to negotiate a licensed entry date before patent expiry [23]. Contract language for this date is standardized enough that legal reference services define “Generic Entry Date” as a defined term: the date, “whether certain or contingent,” on which a generic filer is authorized to begin marketing, sometimes tied to a specific calendar date and sometimes tied to a triggering event such as a court ruling or a competitor’s at-risk launch [19].<\/p>\n\n\n\n

    An early Federal Trade Commission review of reverse-payment settlements for top-selling drugs found agreed entry dates ranging from 30 to 100 months after the settlement itself, with compensation running from the brand company to the generic challenger in exchange for the delay [39].<\/p>\n\n\n\n

    The point for a 340B compliance officer: the people who know the real, contractually binding entry date are the manufacturer’s litigators, the generic challenger’s litigators, and whichever patent-intelligence platform picked up the settlement filing [32]. That date frequently does not match the date a public patent register would suggest, and it is sometimes not public at all until years later.<\/p>\n\n\n\n

    What 340B Contract Pharmacy Networks Track<\/h3>\n\n\n\n

    Contract pharmacies, the TPAs that run split-billing and accumulator software on a covered entity’s behalf, and the wholesalers that replenish 340B inventory do not read settlement agreements. They react to three kinds of downstream signals: the drug’s NDC-level listing in commercial pricing and eligibility files, HRSA’s quarterly Office of Pharmacy Affairs Information System (OPAIS) ceiling-price data, and manufacturer notices posted to HRSA’s own site when an NDC changes [10][16][17]. None of those three sources is a patent docket, and none of them is designed to answer the question “does this drug’s settlement allow generic entry yet.” They are designed to answer a narrower, mechanical question: what NDC is being purchased, and what is today’s ceiling price for it.<\/p>\n\n\n\n

    Where Compendia and TPA Feeds Get Their Data<\/h4>\n\n\n\n

    When a manufacturer changes an NDC, whether because of a formulation update, a new labeler, or a generic launch, HRSA posts a formal notice, and the manufacturer typically states whether accumulated 340B replenishment under the old NDC will carry over to the new one. Cipla’s 2026 notice for filgrastim-txid (NYPOZI) and Viatris’s earlier notice for remifentanil (ULTIVA) both follow this template: the new NDC represents the same product, and covered entities using a compliant replenishment model may count old-NDC accumulations toward the new NDC [16][17]. These notices are useful and necessary, but they answer an inventory-continuity question, not a legal-authorization question. A covered entity’s TPA can process a manufacturer’s NDC change notice perfectly and still be months behind the actual date a generic competitor was legally free to enter, because that date lived in a settlement neither HRSA nor the TPA had access to.<\/p>\n\n\n\n

    Case Study: Truvada’s Two Calendars<\/h2>\n\n\n\n

    Gilead’s HIV drug Truvada is the clearest public illustration of a settlement date outrunning the patent-expiration date most people were tracking.<\/p>\n\n\n\n

    The Settlement Date Nobody Outside the Deal Knew<\/h3>\n\n\n\n

    Teva filed an ANDA for a generic version of Truvada (emtricitabine\/tenofovir disoproxil fumarate) and challenged Gilead’s patents in 2008. The dispute reached a settlement in 2014. Under that agreement, Teva could not launch until the emtricitabine patent’s expected expiration around September 2021, based on public information available at the time [26]. In its quarterly filing with the SEC years later, Gilead disclosed that, under the settlement, Teva would be permitted to launch its generic version on September 30, 2020, a full year earlier than the patent-expiration date most observers, including HIV-prevention advocates who had been tracking Orange Book listings, had assumed [25][26]. The FDA had granted tentative approval of Teva’s ANDA back in 2017, but the actual, controlling date lived in the confidential settlement, not in any FDA approval letter [24].<\/p>\n\n\n\n

    What Changed at the NDC Level<\/h3>\n\n\n\n

    Teva’s generic launched on schedule on September 30, 2020 [27]. Because Teva had technically forfeited its original 180-day first-to-file exclusivity by missing an FDA final-approval deadline years earlier, the settlement itself functioned as the mechanism that granted Teva a de facto exclusivity window: no other generic could enter for roughly six months after that date [28]. That detail became central to a later antitrust trial. A group of insurers and health plans sued Gilead and Teva, alleging the arrangement was an illegal “reverse payment” that used exclusivity, not cash, as the consideration for delay [28][29]. A jury in the Northern District of California found Gilead and Teva not liable on June 30, 2023 [28].<\/p>\n\n\n\n

    What the Trial Record Confirms<\/h4>\n\n\n\n

    Whatever the antitrust merits, the trial record confirms the operational point that matters here: Gilead’s outside counsel and Teva’s outside counsel both knew, years in advance, an entry date the public could not verify from a patent register, and that date differed by about twelve months from the date the underlying patent life would otherwise imply. Any 340B contract pharmacy network relying only on Orange Book expiration dates rather than the settlement date would have modeled Truvada’s transition to multi-source, lower-URA pricing a year later than the transition actually needed to be reflected in the market.<\/p>\n\n\n\n

    Case Study: Xtampza ER and a Generic Entry Date Thirteen Years Out<\/h2>\n\n\n\n

    Truvada shows a settlement pulling entry earlier than expected. Collegium Pharmaceutical’s Xtampza ER settlement with Teva shows the opposite: a specific, real, currently binding generic entry date that will not arrive for years, disclosed only because securities law required it.<\/p>\n\n\n\n

    In September 2020, Collegium announced it had resolved Paragraph IV litigation with Teva over Xtampza ER, an abuse-deterrent opioid. The settlement, filed as an exhibit to a Form 8-K, granted Teva a license to market its generic “in the United States beginning on or after September 2, 2033,” subject to FDA approval of Teva’s ANDA and to acceleration under specified circumstances [30]. That date is not an estimate. It is a contractual term, sitting in a public SEC filing rather than in the Orange Book, and it is exactly the kind of fact a patent-intelligence platform is built to surface and a 340B drug-file feed has no native reason to contain. A covered entity’s contract pharmacy network has no operational reason to model a 2033 entry date today, but a manufacturer’s legal team, and the analysts who track its patent estate, already treat it as fixed unless the “acceleration” trigger fires.<\/p>\n\n\n\n

    The Mechanics: How a Generic Entry Date Changes What a Contract Pharmacy Pays<\/h2>\n\n\n\n

    AMP Minus URA, in Plain Terms<\/h3>\n\n\n\n

    The 340B ceiling price is not a manufacturer’s list price minus a flat discount. It is a formula tied to the Medicaid Drug Rebate Program: Average Manufacturer Price (AMP) for the smallest billable unit, minus the Unit Rebate Amount (URA), calculated separately for each 11-digit NDC [12]. The minimum URA is 23.1% of AMP for most brand-name drugs, 17.1% for brand-name pediatric drugs and clotting factors, and 13% for generic and over-the-counter drugs [9]. A manufacturer must pay a larger rebate, and therefore offer a lower 340B ceiling price, if its best commercial price falls below that floor or if the drug’s price has risen faster than inflation [9][10].<\/p>\n\n\n\n

    The New-NDC Pricing Lag<\/h3>\n\n\n\n

    When any new covered outpatient drug NDC enters the market, brand or generic, there is no AMP history to calculate a ceiling price from yet. HRSA’s 2017 final rule requires manufacturers to estimate a price using wholesale acquisition cost (WAC) minus the applicable rebate percentage until real AMP data exists, which by regulation takes roughly three to four calendar quarters to accumulate: the first AMP is calculated within 30 days of the start of the second quarter after launch, making it effective in the third quarter, with the ceiling price finally in place by the fourth quarter [11][12]. If the estimate turns out too high, the manufacturer owes covered entities a refund [13]. That three-to-four-quarter runway is a separate lag from the settlement-versus-registry gap described above, but it compounds it: even once a generic’s actual legal entry date has passed, its NDC may spend the better part of a year priced on an estimate rather than a calculated AMP-URA ceiling.<\/p>\n\n\n\n

    Penny Pricing and the Multi-Source Threshold<\/h3>\n\n\n\n

    Once real AMP data accumulates for a generic with several competing manufacturers, AMP is often low and the required rebate is often high enough that AMP minus URA works out to zero or a negative number. HRSA’s long-standing “penny pricing” policy resolves that by setting the 340B ceiling price at $0.01 whenever the formula would otherwise produce zero or less [11][14]. This is not an edge case: it is the normal steady state for many mature, multi-source generics, and it represents the deepest possible 340B discount available on a drug [14].<\/p>\n\n\n\n

    When Penny Pricing Applies<\/h4>\n\n\n\n

    Penny pricing typically becomes available only after enough AMP history exists to reflect real generic competition, meaning a covered entity cannot assume it applies the day a generic technically becomes legal to sell. Between the settlement date, the actual launch date, and the date AMP data reflects a competitive market, there are potentially three separate transition points, each with its own timing, and only the first two are visible to a legal or regulatory affairs team tracking a docket.<\/p>\n\n\n\n

    Where the Break Happens: TPAs, Accumulators, and Manufacturer Notices<\/h2>\n\n\n\n

    NDC Change Notices Are Not Settlement Notices<\/h3>\n\n\n\n

    HRSA maintains a running public list of manufacturer notices covering NDC changes, price adjustments, and refunds, and 340B contract pharmacy TPAs generally build their eligibility and pricing feeds around this list plus the OPAIS quarterly ceiling-price file [10][15][16][17]. Manufacturers such as Viatris and Cipla have used this channel to announce routine NDC replacements unrelated to patent status, explicitly stating the new NDC’s 340B treatment mirrors the old one [16][17]. These are useful, well-structured notices, but they exist to prevent inventory replenishment errors, not to announce that a patent settlement has quietly reached its trigger date. A generic launch driven by a confidential settlement produces no equivalent standardized notice pointed at 340B stakeholders; the market simply learns about it through a press release, an SEC filing, or a drug-pricing compendium update, on whatever timetable the manufacturer or the generic challenger chooses to disclose it.<\/p>\n\n\n\n

    340B ESP, Claims-Data Mandates, and a Second Data Lag<\/h3>\n\n\n\n

    Since 2020, a growing list of manufacturers, including Eli Lilly and Exelixis, have required covered entities to submit contract pharmacy claims data through the 340B ESP platform, operated by the vendor Second Sight Solutions, as a condition of continued 340B pricing eligibility [18][38]. Lilly’s policy covers its full portfolio under specific labeler codes and generally requires data submission within 45 days of dispense, or 60 days for certain clinic-administered products [18]. Sanofi and Novo Nordisk built similar data-sharing conditions into the contract pharmacy access policies they adopted after October 2020, conditioning unlimited contract pharmacy shipment on a covered entity’s agreement to share claims data through the same 340B ESP tool [38]. These mandates add a second, independent data pipeline running in parallel to NDC pricing feeds, one built to verify claim-level eligibility rather than to track patent status, and covered entities now have to reconcile that pipeline, their TPA’s pricing tables, and whatever their legal team knows about a drug’s actual patent and settlement posture, none of which were designed to talk to each other.<\/p>\n\n\n\n

    A Working Taxonomy of Generic Entry Dates<\/h2>\n\n\n\n

    For internal reconciliation purposes, it helps to name the distinct dates that can all get called “the generic entry date” for a single drug. Patent-intelligence platforms commonly publish a single estimated “generic entry opportunity date” per drug, built from patent-expiration analysis, and are explicit that the real date can move earlier or later depending on litigation and settlement outcomes [31]. The table below breaks that single estimate into the separate dates a 340B compliance program actually has to reconcile. This is an original classification for operational use, not an established regulatory term.<\/p>\n\n\n\n

    Type<\/th>What it reflects<\/th>Who typically knows it first<\/th>Where it is documented<\/th><\/tr>
    Patent-expiration date<\/td>The last date an unexpired, unchallenged patent blocks generic entry<\/td>Patent-intelligence analysts, IP counsel<\/td>Orange Book, USPTO records<\/td><\/tr>
    Regulatory-exclusivity date<\/td>Statutory exclusivity (e.g., new chemical entity, orphan, pediatric) independent of any patent<\/td>Regulatory affairs<\/td>FDA Orange Book exclusivity codes<\/td><\/tr>
    Settlement date (certain)<\/td>A fixed calendar date a Paragraph IV settlement grants for generic launch<\/td>Litigators, outside counsel<\/td>Settlement agreement; sometimes an SEC filing<\/td><\/tr>
    Settlement date (contingent)<\/td>A date tied to a triggering event (e.g., a court ruling, a third party’s at-risk launch)<\/td>Litigators, outside counsel<\/td>Settlement agreement; rarely public until triggered<\/td><\/tr>
    Actual market-launch date<\/td>The date a generic is physically shipped and dispensed<\/td>Wholesalers, pharmacies<\/td>NDC activation in distribution and claims systems<\/td><\/tr>
    340B-eligible pricing date<\/td>The date a generic NDC’s ceiling price reflects real AMP-URA data, potentially including penny pricing<\/td>340B TPAs, HRSA OPAIS<\/td>OPAIS quarterly pricing file<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

    A covered entity’s compliance program is only as good as its weakest link in this chain. Legal teams generally have strong visibility into the first four rows and weak visibility into the last two. 340B pharmacy operations have the reverse problem.<\/p>\n\n\n\n

    What’s at Stake: Sizing the Exposure<\/h2>\n\n\n\n

    The Program Has Never Been Larger<\/h3>\n\n\n\n

    Covered entities purchased $100.0 billion in covered outpatient drugs through the 340B program in calendar year 2025, up from $81.4 billion in 2024, $66.3 billion in 2023, and just $43.9 billion as recently as 2021, a 23% year-over-year jump in 2025 alone [1][2][3][4][5]. Disproportionate share hospitals alone accounted for roughly 79% of 2025 purchases, and all 340B hospitals combined accounted for close to 87% [1][7]. As early as 2023, 340B purchases already represented approximately 16% of all U.S. drug spending [8]. More than 31,500 unique contract pharmacy locations (32,069 as of mid-2025, per Drug Channels Institute), tied to nearly 240,000 contractual relationships, dispense a meaningful share of that volume on covered entities’ behalf [6][7].<\/p>\n\n\n\n

    \n

    Independent analysis of the program’s growth trajectory puts 340B purchase growth at roughly three to five times the pace of overall U.S. drug spending growth over the past decade, whether measured by the Congressional Budget Office, Drug Channels Institute, or IQVIA [7].<\/p>\n<\/blockquote>\n\n\n\n

    Specialty Concentration Raises the Stakes of Getting One NDC Wrong<\/h3>\n\n\n\n

    Specialty pharmaceuticals, exactly the category most likely to carry complex, multi-patent, heavily litigated exclusivity profiles, made up only 38.1% of 340B units purchased in 2025 but 61.9% ($61.9 billion) of purchase dollars [1]. The top 10 drugs by 340B purchase volume accounted for roughly 28.6% of total 2025 program spending [1]. In 2024, the top five 340B drugs by purchase volume were Keytruda ($8.16 billion), Biktarvy ($4.19 billion), Darzalex Faspro ($2.46 billion), Opdivo ($2.15 billion), and Trikafta ($2.07 billion) [2]. These are precisely the products where patent thickets, orphan-drug exclusivity, and staggered Paragraph IV settlements across multiple challengers are most common, and where a single NDC’s mispriced quarter can represent a meaningful dollar swing given the purchase volumes involved.<\/p>\n\n\n\n

    Top Five 340B Drugs by Purchase Volume, 2024<\/h4>\n\n\n\n
    Brand<\/th>Primary Indication<\/th>2024 Total 340B Purchases<\/th><\/tr>
    Keytruda<\/td>Oncology<\/td>$8.16 billion<\/td><\/tr>
    Biktarvy<\/td>HIV<\/td>$4.19 billion<\/td><\/tr>
    Darzalex Faspro<\/td>Oncology<\/td>$2.46 billion<\/td><\/tr>
    Opdivo<\/td>Oncology<\/td>$2.15 billion<\/td><\/tr>
    Trikafta<\/td>Cystic Fibrosis<\/td>$2.07 billion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

    Source: HRSA, 2024 340B Covered Entity Purchases [2].<\/p>\n\n\n\n

    The Legal Landscape Layered on Top of the Pricing Mechanics<\/h2>\n\n\n\n

    The generic entry date mismatch does not happen in a stable regulatory environment. It happens against an active, multi-circuit legal fight over whether manufacturers can restrict which contract pharmacies receive 340B pricing at all, which changes who is even positioned to catch a pricing error before it compounds.<\/p>\n\n\n\n

    Sanofi-Aventis U.S. LLC v. HHS (Third Circuit, 2023)<\/h3>\n\n\n\n

    On January 30, 2023, the Third Circuit ruled that Section 340B does not require manufacturers to ship discounted drugs to an unlimited number of contract pharmacies, enjoining HHS from enforcing a contrary interpretation against Sanofi, Novo Nordisk, and AstraZeneca specifically [33][35][36]. The ruling did not resolve whether manufacturers could refuse contract pharmacies entirely, but it sustained the shipment restrictions those three manufacturers had already adopted in late 2020 [38].<\/p>\n\n\n\n

    Novartis Pharmaceuticals Corp. v. Johnson (D.C. Circuit, 2024)<\/h3>\n\n\n\n

    The D.C. Circuit reached a similar conclusion on May 21, 2024, holding that Section 340B’s silence on distribution mechanics cannot be read to force manufacturers into whatever delivery terms HHS prefers [34][37]. Combined with the Third Circuit ruling, this left contract-pharmacy restriction policy resting primarily on manufacturer discretion and state law, not on a uniform federal floor.<\/p>\n\n\n\n

    PhRMA v. McClain and State Nondiscrimination Statutes<\/h3>\n\n\n\n

    States responded with laws barring manufacturers from restricting contract pharmacy access within their borders. The Eighth Circuit upheld Arkansas’s nondiscrimination statute in PhRMA v. McClain, and the Supreme Court declined to review that decision in December 2024, letting the pro-state ruling stand [18]. The practical result for a covered entity is a patchwork: whether its contract pharmacy network can even access a given manufacturer’s 340B pricing at all now depends on which state it operates in, layered directly on top of the generic entry date questions described above.<\/p>\n\n\n\n

    What This Means for Diversion, Duplicate Discount, and Overcharge Exposure<\/h2>\n\n\n\n

    Overcharge Risk When the Network Lags the Settlement<\/h3>\n\n\n\n

    If a manufacturer’s own systems have not yet reclassified an NDC after a settlement-driven generic entry, and a covered entity’s TPA is still invoicing at the prior brand-tier ceiling price, the covered entity is simply paying more than the statute allows for that period once the correct price is later established, entitling it to a refund once the discrepancy surfaces [13]. HRSA’s rules require manufacturers to issue refunds within a defined window once an overcharge is identified, but identifying it in the first place depends on someone comparing the invoiced price against the correct one, a comparison that requires knowing the real entry date [13].<\/p>\n\n\n\n

    Lost Savings When the Settlement Date Passes Quietly<\/h3>\n\n\n\n

    The more common and less visible failure mode is not an overcharge dispute; it is a missed opportunity. If a covered entity’s contract pharmacy network continues purchasing a brand NDC at a 23.1%-URA ceiling price for months after a settlement-driven generic entry date has passed, simply because no manufacturer notice or drug-file update triggered a review, the entity is leaving the deeper, often penny-priced generic discount on the table with no compliance violation to flag it. This is a lost-savings problem, not a legal exposure, but at the purchase volumes involved in the 340B program’s top drugs, even a short lag has real financial weight.<\/p>\n\n\n\n

    Duplicate Discount Risk at the NDC Transition<\/h3>\n\n\n\n

    Contract pharmacies must carve out Medicaid patients from 340B dispensing unless the covered entity has a documented arrangement with the state Medicaid agency listed on HRSA’s Medicaid Exclusion File [15]. An NDC transition around a generic launch is exactly the kind of event that can disrupt that bookkeeping: if accumulator systems are still tracking the old NDC while claims data starts flowing under the new one, a covered entity risks either a duplicate discount (the same unit receiving both a 340B discount and a Medicaid rebate) or a diversion finding during a HRSA audit, both of which are recurring findings in HRSA’s published covered-entity audit results [7].<\/p>\n\n\n\n

    Methodology<\/h2>\n\n\n\n

    This analysis draws on primary sources wherever they exist: FDA guidance on Paragraph IV certifications, HRSA’s 340B statute implementation and manufacturer notices, the Federal Register’s 340B ceiling price final rule, and SEC filings disclosing specific settlement terms. The two case studies, Truvada and Xtampza ER, were selected because each has a specific, dated, and independently verifiable generic entry date documented in a public regulatory or securities filing, rather than an estimate. Program-scale figures (purchase totals, contract pharmacy counts, drug-level purchase volumes) come from HRSA’s own annual covered-entity purchase reports and are the same figures HRSA itself publishes and periodically updates; readers should expect 2026 and later figures to differ once HRSA releases them. This piece does not claim to have identified a specific, currently mispriced NDC at any named covered entity; confidential settlement terms are, by definition, not publicly auditable at that level of specificity, and the exposure described here is structural and directional rather than a named instance of noncompliance.<\/p>\n\n\n\n

    What Covered Entities, Contract Pharmacies, and Legal Teams Should Do Now<\/h2>\n\n\n\n

    For Legal and Regulatory Affairs Teams<\/h3>\n\n\n\n

    Flag settlement-driven generic entry dates, especially contingent ones, to the 340B compliance function as soon as they are known internally or discovered through patent-intelligence monitoring, rather than assuming pharmacy operations will independently notice a court filing or an SEC disclosure.<\/p>\n\n\n\n

    For 340B Compliance and Pharmacy Operations<\/h3>\n\n\n\n

    Build a standing reconciliation step that checks high-volume specialty NDCs against known settlement dates on a quarterly cadence, matching the same cadence HRSA uses to update OPAIS ceiling prices, rather than waiting for a manufacturer NDC change notice that may never come in the exact form expected.<\/p>\n\n\n\n

    For IT and TPA Configuration<\/h3>\n\n\n\n

    Confirm with contract pharmacy TPAs and drug-file vendors exactly which data feed determines a drug’s brand-or-generic classification for URA purposes, how frequently it updates, and whether it has any mechanism for manual override when legal or patent-intelligence sources identify a date the feed has not yet caught up to.<\/p>\n\n\n\n

    Frequently Asked Questions<\/h2>\n\n\n\n

    What is a “generic entry date” in a patent settlement? It is a contractual term in a Paragraph IV settlement agreement specifying when a generic challenger may lawfully begin marketing its product, which can be a fixed calendar date or a date contingent on a future event such as a court ruling [19].Why doesn’t a 340B contract pharmacy network automatically know the settlement date? Contract pharmacy TPAs and drug-pricing feeds are built around NDC listings, HRSA’s OPAIS ceiling-price file, and manufacturer notices, not litigation dockets or confidential settlement agreements, which are often not public at all until a party discloses them [10][15][19].What is 340B “penny pricing,” and when does it start? Penny pricing sets a drug’s 340B ceiling price at $0.01 whenever the AMP-minus-URA formula would otherwise produce zero or a negative number, a common result once a generic has several competing manufacturers and a low AMP. It generally requires several quarters of real AMP data after entry, not just a legal green light to launch [11][14].Does a covered entity lose money if its network is slow to reflect a generic entry date? Potentially, in the form of forgone savings rather than a compliance penalty: continuing to purchase at a brand-tier ceiling price after a lower generic price is technically available is a missed discount, not an overcharge, unless the entity paid above the correct ceiling price for the NDC actually invoiced.Can a covered entity face compliance risk from a mismatched NDC transition? Yes. Accumulator and replenishment errors during an NDC transition can contribute to diversion or duplicate discount findings, both recurring categories in HRSA’s published covered-entity audit results [7].Who actually holds the real generic entry date if it’s confidential? Typically the litigating parties’ outside counsel and, once filed, whichever regulatory body received a required disclosure, such as the SEC for a public company’s material settlement, as in Collegium’s Xtampza ER disclosure, or the FTC under its Medicare Modernization Act settlement-reporting authority [30][39].How does the 30-month stay affect the timeline a covered entity should expect? A timely-filed infringement suit triggers a stay of FDA approval for up to 30 months, but a peer-reviewed study of 46 generic drugs found a median gap of 3.2 years between stay expiration and actual generic launch, meaning the stay period itself is rarely the binding constraint on when entry actually occurs [21][22].Are manufacturer NDC change notices the same as generic entry notices? No. NDC change notices, such as those Viatris and Cipla have posted through HRSA, address inventory and replenishment continuity for a relabeled or reformulated product. They are not a standardized channel for announcing that a Paragraph IV settlement’s entry date has arrived [16][17].How do contract pharmacy restrictions complicate this further? Since the Third Circuit’s 2023 Sanofi-Aventis ruling and the D.C. Circuit’s 2024 Novartis ruling, manufacturers can lawfully limit which contract pharmacies receive 340B pricing at all, meaning the entity responsible for catching a generic-entry pricing error may not be the same entity actually dispensing the drug [34][35].What should legal and pharmacy operations teams do to reconcile their calendars? Establish a direct, recurring handoff between whoever tracks patent and settlement intelligence and whoever configures 340B pricing and eligibility systems, rather than relying on downstream manufacturer notices or drug compendia to surface a settlement date on their own.<\/p>\n\n\n\n

    Key Takeaways<\/h2>\n\n\n\n
      \n
    • A “generic entry date” can mean a patent-expiration date, a regulatory-exclusivity date, a certain or contingent settlement date, an actual launch date, or a 340B-eligible pricing date, and these five dates are frequently not the same day [19].<\/li>\n\n\n\n
    • Settlement dates are legally binding but can be confidential, and they have moved real drugs a full year earlier (Truvada, 2020) or more than a decade into the future (Xtampza ER, 2033) relative to what a public patent registry alone would show [26][30].<\/li>\n\n\n\n
    • The 340B ceiling price is an NDC-specific AMP-minus-URA calculation, and the URA floor drops from 23.1% for most brand drugs to 13% for generics, with many mature generics ultimately reaching the $0.01 “penny pricing” floor [9][11][14].<\/li>\n\n\n\n
    • New NDCs, brand or generic, typically take three to four calendar quarters before a real AMP-based ceiling price replaces an estimated one, adding a second lag on top of any gap between the settlement date and the public record [11][12].<\/li>\n\n\n\n
    • Contract pharmacy TPAs and manufacturer NDC change notices are built to manage inventory and eligibility mechanics, not to broadcast settlement-driven entry dates, leaving legal and compliance teams to build that bridge themselves [15][16][17].<\/li>\n\n\n\n
    • The dollar stakes are rising: 340B purchases reached $100.0 billion in 2025, increasingly concentrated in specialty drugs with the most complex patent and exclusivity profiles [1][7].<\/li>\n<\/ul>\n\n\n\n

      References<\/h2>\n\n\n\n
        \n
      1. Health Resources and Services Administration. (2026). 2025 340B Covered Entity Purchases.<\/em> https:\/\/www.hrsa.gov\/opa\/updates\/2025-340b-covered-entity-purchases<\/li>\n\n\n\n
      2. Health Resources and Services Administration. (2025). 2024 340B Covered Entity Purchases.<\/em> https:\/\/www.hrsa.gov\/opa\/updates\/2024-340b-covered-entity-purchases<\/li>\n\n\n\n
      3. Health Resources and Services Administration. 2021 340B Covered Entity Purchases.<\/em> https:\/\/hrsa.gov\/opa\/updates\/2021-340b-covered-entity-purchases<\/li>\n\n\n\n
      4. Citizens Against Government Waste. (2026, July 28). 340B Purchases Exceeded $100 Billion in 2025.<\/em> https:\/\/www.cagw.org\/340b-purchases-exceeded-100-billion-in-2025\/<\/li>\n\n\n\n
      5. Avalere Health. 340B Purchases Surge Past $100 Billion.<\/em> https:\/\/advisory.avalerehealth.com\/insights\/340b-purchases-surge-past-100-billion<\/li>\n\n\n\n
      6. Drug Channels Institute. (2025, October). The 340B Contract Pharmacy Market in 2025: Big Chains and PBMs Tighten Their Grip.<\/em> https:\/\/www.drugchannels.net\/2025\/10\/the-340b-contract-pharmacy-market-in.html<\/li>\n\n\n\n
      7. IntuitionLabs. (2026, August 9). 340B Program Statistics 2026: Covered Entities & Discount Value.<\/em> https:\/\/intuitionlabs.ai\/articles\/340b-program-statistics-2026<\/li>\n\n\n\n
      8. American Journal of Managed Care. Association Between 340B Contract Pharmacy Growth and Payer-Specific Drug Coverage.<\/em> https:\/\/www.ajmc.com\/view\/association-between-340b-contract-pharmacy-growth-and-payer-specific-drug-coverage<\/li>\n\n\n\n
      9. 340B Health. Key Terms.<\/em> https:\/\/www.340bhealth.org\/members\/340b-program\/key-terms\/<\/li>\n\n\n\n
      10. 340B Health. 340B Drug Pricing Program Overview.<\/em> https:\/\/www.340bhealth.org\/members\/340b-program\/overview\/<\/li>\n\n\n\n
      11. Federal Register. (2017, January 5). 340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties Regulation.<\/em> https:\/\/www.federalregister.gov\/documents\/2017\/01\/05\/2016-31935\/340b-drug-pricing-program-ceiling-price-and-manufacturer-civil-monetary-penalties-regulation<\/li>\n\n\n\n
      12. Powers Pyles Sutter and Verville PC. HRSA Publishes Final Rule Addressing 340B Ceiling Price Calculations and Manufacturer Penalties for Overcharging.<\/em> https:\/\/www.powerslaw.com\/hrsa-publishes-final-rule-addressing-340b-ceiling-price-calculations-manufacturer-penalties-overcharging\/<\/li>\n\n\n\n
      13. K&L Gates. 340B Update: HRSA Accelerates Implementation of Long-Delayed 340B Pricing and Manufacturer Penalties Rule.<\/em> https:\/\/www.klgates.com\/340B-Update-HRSA-Accelerates-Implementation-of-Long-Delayed-340B-Pricing-and-Manufacturer-Penalties-Rule<\/li>\n\n\n\n
      14. Virtue 340B. Penny Pricing.<\/em> https:\/\/virtue340b.com\/glossary-term\/penny-pricing\/<\/li>\n\n\n\n
      15. Health Resources and Services Administration, 340B Prime Vendor Program. Contract Pharmacy Services.<\/em> https:\/\/hrsa.gov\/opa\/implementation-contract<\/li>\n\n\n\n
      16. Health Resources and Services Administration. Viatris Notice Regarding NDC Changes.<\/em> https:\/\/www.hrsa.gov\/sites\/default\/files\/hrsa\/opa\/viatris-notice-regarding-ndc-changes.pdf<\/li>\n\n\n\n
      17. Health Resources and Services Administration. Cipla NYPOZI NDC Change Letter.<\/em> https:\/\/www.hrsa.gov\/sites\/default\/files\/hrsa\/opa\/cipla-nypozi-ndc-change-letter.pdf<\/li>\n\n\n\n
      18. Frier Levitt. 340B Manufacturer Data Demands: What Covered Entities and Contract Pharmacies Need to Know.<\/em> https:\/\/www.frierlevitt.com\/articles\/340b-manufacturer-data-demands-claim-level-compliance-risks\/<\/li>\n\n\n\n
      19. Law Insider. Generic Entry Date Definition.<\/em> https:\/\/lawinsider.com\/dictionary\/generic-entry-date<\/li>\n\n\n\n
      20. U.S. Food and Drug Administration. Patent Certifications and Suitability Petitions.<\/em> https:\/\/www.fda.gov\/drugs\/abbreviated-new-drug-application-anda\/patent-certifications-and-suitability-petitions<\/li>\n\n\n\n
      21. Fish & Richardson. Hatch-Waxman 101.<\/em> https:\/\/www.fr.com\/insights\/thought-leadership\/blogs\/hatch-waxman-101-3\/<\/li>\n\n\n\n
      22. National Center for Biotechnology Information. Study of 30-Month Stays and Generic Entry Timing (Cohort of 46 Generic Drugs).<\/em> https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8504843\/<\/li>\n\n\n\n
      23. National Bureau of Economic Research. Most-Favored Entry Clauses in Drug Patent Litigation Settlements.<\/em> https:\/\/www.nber.org\/system\/files\/working_papers\/w29801\/w29801.pdf<\/li>\n\n\n\n
      24. BioPharma Dive. FDA Approves Teva’s Generic Copy of Truvada.<\/em> https:\/\/www.biopharmadive.com\/news\/teva-truvada-fda-generic-approval-gilead\/445006\/<\/li>\n\n\n\n
      25. GaBI Online. Gilead’s Truvada Will Face Generics Competition in 2020.<\/em> https:\/\/www.gabionline.net\/generics\/general\/Gilead-s-Truvada-will-face-generics-competition-in-2020<\/li>\n\n\n\n
      26. POZ. Generic PrEP to Arrive in September 2020, but Will Big Savings Follow?<\/em> https:\/\/www.poz.com\/article\/generic-prep-arrive-september-2020-will-big-savings-follow<\/li>\n\n\n\n
      27. POZ. First Generic Truvada Now Available in the United States.<\/em> https:\/\/www.poz.com\/article\/first-generic-truvada-now-available-united-states<\/li>\n\n\n\n
      28. Wilson Sonsini. Jury Finds Gilead and Teva Did Not Engage in an Anticompetitive Pay-for-Delay Scheme for HIV Drugs.<\/em> https:\/\/www.wsgr.com\/en\/insights\/jury-finds-gilead-and-teva-did-not-engage-in-an-anticompetitive-pay-for-delay-scheme-for-hiv-drugs.html<\/li>\n\n\n\n
      29. Crowell & Moring. HIV Drug Buyers Urge $3.6B Verdict Against Gilead and Teva.<\/em> https:\/\/www.crowell.com\/a\/web\/sGBrt9t5grfJz2jmQLCNGe\/hiv-drug-buyers-urge-dollar36b-verdict-against-gilead-and-teva.pdf<\/li>\n\n\n\n
      30. U.S. Securities and Exchange Commission (EDGAR). Collegium Pharmaceutical, Inc., Form 8-K, Exhibit 99.1: Collegium Announces Settlement with Teva Resolving Xtampza ER Patent Litigation.<\/em> https:\/\/www.sec.gov\/Archives\/edgar\/data\/1267565\/000110465920110179\/tm2031781d2_ex99-1.htm<\/li>\n\n\n\n
      31. DrugPatentWatch. United States: Drugs Facing Patent Expirations and Generic Entry Opportunity Dates.<\/em> https:\/\/www.drugpatentwatch.com\/p\/generic-entry-opportunity-date\/<\/li>\n\n\n\n
      32. DrugPatentWatch. The Patent Cliff and Beyond: A Definitive Guide to Generic and Biosimilar Market Entry.<\/em> https:\/\/www.drugpatentwatch.com\/blog\/generic-drug-entry-timeline-predicting-market-dynamics-after-patent-loss\/<\/li>\n\n\n\n
      33. Foley Hoag LLP. Third Circuit Holds That Drug Manufacturers Are Not Required to Contract with Unlimited 340B Contract Pharmacies.<\/em> https:\/\/foleyhoag.com\/news-and-insights\/publications\/alerts-and-updates\/2023\/february\/united-states-court-of-appeals-for-the-third-circuit-holds-that-drug-manufacturers-are-not-required\/<\/li>\n\n\n\n
      34. Foley Hoag LLP. D.C. Circuit Holds 340B Program Does Not Prohibit Drug Manufacturers from Imposing Contract Pharmacy Restrictions.<\/em> https:\/\/foleyhoag.com\/news-and-insights\/publications\/alerts-and-updates\/2024\/may\/dc-circuit-holds-340b-program-does-not-prohibit-drug-manufacturers-from-imposing-contract-pharmacy\/<\/li>\n\n\n\n
      35. American Society of Health-System Pharmacists. Third Circuit Court of Appeals Rules in Favor of Drugmakers in 340B Contract Pharmacy Case.<\/em> https:\/\/news.ashp.org\/news\/ashp-news\/2023\/01\/31\/third-circuit-court-of-appeals-rules-in-favor-of-drugmakers-in-340b-contract-pharmacy-case<\/li>\n\n\n\n
      36. Reed Smith LLP. Third Circuit Issues First Appellate Ruling in 340B Contract Pharmacy Litigation.<\/em> https:\/\/www.reedsmith.com\/articles\/third-circuit-first-appellate-ruling-340b-contract-pharmacy-litigation\/<\/li>\n\n\n\n
      37. Congressional Research Service. The 340B Drug Discount Program: Litigation Topics and Trends<\/em> (R48696). https:\/\/www.congress.gov\/crs-product\/R48696<\/li>\n\n\n\n
      38. Feldesman LLP. 340B Contract Pharmacy Relationships in Jeopardy After Ruling.<\/em> https:\/\/www.feldesman.com\/client-alert-multiple-340b-contract-pharmacy-relationships-in-serious-jeopardy-after-third-circuit-ruling\/<\/li>\n\n\n\n
      39. Federal Trade Commission. Agreements Filed with the Federal Trade Commission Under the Medicare Prescription Drug, Improvement, and Modernization Act: FY2005 Report to Congress.<\/em> https:\/\/www.ftc.gov\/sites\/default\/files\/documents\/reports\/agreements-filed-federal-trade-commission-under-medicare-prescription-drug-improvement-and\/fy2005drugsettlementsrpt.pdf<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

        DrugPatentWatch tracks generic entry dates for a living, and one pattern shows up over and over in support calls from […]<\/p>\n","protected":false},"author":1,"featured_media":39664,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-39662","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/39662","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=39662"}],"version-history":[{"count":0,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/39662\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/39664"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=39662"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=39662"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=39662"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}